Mankind Pharma , India's fourth-largest pharmaceutical company, has reported a robust 20.8% year-over-year revenue growth for the second quarter of fiscal year 2026, reaching INR 3,697.00 crore. The company's performance was primarily driven by strong growth in its chronic segment and the successful integration of Bharat Serums and Vaccines Limited (BSV).

Financial Highlights

• Revenue from operations increased by 20.8% YoY to INR 3,697.00 crore
• Domestic revenue grew by 14.5% to INR 3,184.00 crore
• EBITDA rose by 8.7% to INR 924.00 crore, with a margin of 25.0%
• Profit After Tax (PAT) stood at INR 520.00 crore, with a margin of 14.1%

Segment Performance

Domestic Business

The domestic business, which contributes 86% of total revenue, showed strong growth:

• Domestic revenue increased by 14.5% YoY
• Chronic segment outperformed with 1.3x growth in Cardiac and 1.2x in Anti-Diabetics
• Improved ranking to #4 in Anti-diabetes segment
• Maintained #1 rank in prescriptions with a 15.3% share

Consumer Healthcare

The consumer healthcare segment faced some challenges:

• Revenue declined by 3% YoY due to supply chain disruptions and uneven monsoon
• Modern Trade & E-commerce share increased to 12% in H1 FY26
• Strong secondary sales growth for key brands like Gas-o-fast (36% YoY) and Manforce Condom (14% YoY)

Exports

The export business showed significant growth:

• Revenue increased by 82.6% YoY, primarily due to BSV consolidation
• Mankind (excluding BSV) launched 3 new products in the US market

Strategic Developments

Mr. Rajeev Juneja, Vice Chairman & Managing Director, commented on the results: "Mankind's revenue increased by 20.8% supported by outperformance in Chronic and BSV consolidation, partially impacted by GST disruption. While chronic continued an outperformance led by 1.3x and 1.2x in Cardiac and Anti-diabetes respectively, OTC was impacted due to heavy rains along with GST 2.0 and we expect growth recovery in H2. BSV growth initiatives progressing well - with double digit sequential growth led by mandate brands."

The company remains focused on four key growth pillars:

1. Steady base business
2. Fast-growing specialty chronic segment
3. High-potential OTC business
4. Super specialty BSV portfolio

Outlook

Mankind Pharma is confident in delivering sustainable long-term growth through its diversified portfolio and strategic initiatives. The company's focus on expanding its chronic segment, integrating BSV's super specialty portfolio, and recovering its OTC business positions it well for future growth in the Indian pharmaceutical market.

Despite challenges such as GST disruptions and uneven monsoons affecting certain segments, Mankind Pharma's overall performance demonstrates its resilience and ability to capitalize on growth opportunities in the pharmaceutical sector.

Mankind Pharma , a prominent player in the Indian pharmaceutical industry, has recently received an Environmental, Social, and Governance (ESG) rating from MSCI ESG Ratings and Research Private Limited. This development marks a significant step in the company's commitment to sustainable and responsible business practices.

ESG Rating Details

Disclosure and Transparency

Mankind Pharma has taken steps to ensure transparency regarding this ESG assessment:

1. The company has made the ESG report available on its official website ( www.mankindpharma.com ).
2. In compliance with SEBI regulations, Mankind Pharma has informed both the BSE Limited and the National Stock Exchange of India Limited about this development.

Regulatory Compliance

The disclosure of the ESG rating aligns with Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This move demonstrates Mankind Pharma's commitment to meeting regulatory standards and maintaining open communication with stakeholders.

Implications of the ESG Rating

While the specific implications of the 'B' rating are not detailed in the provided information, ESG ratings generally offer insights into a company's performance across environmental, social, and governance factors. These ratings may influence investor perceptions and decisions, particularly for those focused on sustainable and responsible investing.

As the pharmaceutical industry faces increasing scrutiny on issues ranging from environmental impact to social responsibility, Mankind Pharma's engagement with ESG ratings indicates its awareness of these evolving market expectations.

Investors and stakeholders may view this rating as a benchmark for Mankind Pharma's current ESG performance and may look for future improvements or initiatives in these areas.